Group 1: Investor Relations Activity - The company participated in the "2023 Guangdong Listed Companies Investor Online Reception Day" on September 19, 2023 [1][2] Group 2: Company Performance and Market Outlook - The management is closely monitoring the potential for transferring to the Beijing Stock Exchange and will disclose any plans in accordance with regulations [3] - The overall pig prices remain low, and the industry is still undergoing capacity reduction, making future performance uncertain [4] - The company’s production capacity utilization is currently high, and there is stability in orders for Q4 and next year [5] Group 3: Product and Market Information - The company offers over 30 types of animal biological products, including vaccines for pigs, poultry, and aquatic animals, with core products ranking highly in market share [6] - Export sales reached 6.95 million yuan in the first half of the year, a 58.64% increase compared to the same period last year, with a focus on expanding into markets like Egypt [7] - The company is actively researching and developing vaccines for African swine fever [8]

| 日期 | 代码 | 简称 | 成交价 | 成交数量（股） | 买入营业部 | 卖出营业部 | | --- | --- | --- | --- | --- | --- | --- | | 2023-09- | | | | | 中泰证券股份有限公 | 万联证券股份有限公 | | 19 | 839729 | 永顺生物 | 7 | 200000 | 司青岛正阳路证券营 | 司广州珠江新城证券 | | | | | | | 业部 | 营业部 | | 2023-09- | 839729 | 永顺生物 | 7 | 300000 | 申万宏源证券有限公 | 万联证券股份有限公 司广州珠江新城证券 | | 19 | | | | | 司吉林分公司 | | | | | | | | | 营业部 | | 2023-09- | 839729 | 永顺生物 | 7 | 300000 | 申万宏源证券有限公 | 万联证券股份有限公 司广州珠江新城证券 | | 19 | | | | | 司吉林分公司 | | | | | | | | | 营业部 | | 2023-09- | 839729 | 永顺生物 | 7 | 300000 | 申万宏源证 ...

证券代码：839729 证券简称：永顺生物 公告编号：2023-065 本次投资者网上集体接待日活动将采用网络远程的方式举行，投资者可登录 "全景路演"网站（https://rs.p5w.net）参与本次互动交流，活动时间为 2023 年 9 月 19 日（周二） 15:45-17:00。 届时公司董事、总经理林德锐先生，副总经理、董事会秘书吴子舟先生，财 务负责人李秋红女士将通过网络在线就公司 2023 年半年度业绩、公司治理、发 展战略、经营状况和可持续发展等投资者关心的问题，与投资者进行沟通与交流， 欢迎广大投资者踊跃参与！ 特此公告。 广东永顺生物制药股份有限公司 董事会 广东永顺生物制药股份有限公司 关于参加 2023 年广东辖区上市公司投资者网上集体接待日活动的 公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带 法律责任。 为了进一步加强与投资者的互动交流，广东永顺生物制药股份有限公司（以 下简称"公司"）将参加由中国证券监督管理委员会广东监管局、广东上市公司 协会联合举办的"2023 年广东辖区上市 ...

证券代码:839729 证券简称: 永顺生物 公告编号:2023-064 广东永顺生物制药股份有限公司 投资者关系活动记录表 本公司及董事会全体成员保证公告内容的真实、准确和完整,没有虚假记载、误 导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带法律 责任。 一、投资者关系活动类别 □特定对象调研 业绩说明会 □媒体采访 □现场参观 □新闻发布会 □分析师会议 □路演活动 □其他 二、投资者关系活动情况 ( 一)活动时间、地点 公司于2023年8月30日(星期三)15:00-17:00在全景网"投资者关系互动平 台" (https://ir.p5w.net)举办2023年半年度报告业绩说明会。 ( 二 ) 公司参与人员 公司董事、总经理:林德锐先生 公司副总经理、董事会秘书:吴子舟先生 公司财务负责人:李秋红女士 公司保荐代表人:张星明先生 三、投资者关系活动主要内容 本次业绩说明会通过半年报视频解读对公司情况及2023年上半年经营业 绩情况进行了介绍。同时公司在业绩说明会上就投资者关心的问题进行了回 答。主要问题及回复概要如下: 问题1:公司截至目前有多少专利及产品证书? 回复:截至2 ...

证券代码：839729 证券简称：永顺生物 公告编号：2023-063 广东永顺生物制药股份有限公司 2023 年半年度报告业绩说明会预告公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 说明会类型 广东永顺生物制药股份有限公司（以下简称"公司"）于 2023 年 8 月 8 日在 北京证券交易所指定信息披露平台（www.bse.cn）披露了《2023 年半年度报告》 （公告编号：2023-058）及《2023 年半年度报告摘要》（公告编号：2023-059）， 为方便广大投资者更深入了解公司 2023 年半年度经营业绩的具体情况，加强与 投资者的互动交流，公司拟召开 2023 年半年度报告业绩说明会。 二、 说明会召开的时间、地点 （一）会议召开时间：2023 年 8 月 30 日（星期三）15：00—17：00。 （二）会议召开地点 本次业绩说明会将采用网络方式召开，投资者可登陆全景网"投资者关系互 动平台"（https://ir.p5w.net）参与本次业绩说明会。 三、 参加人员 公司 ...

Financial Performance - The company's operating revenue for the first half of 2023 was CNY 152,714,720.89, a decrease of 1.80% compared to CNY 155,508,444.83 in the same period last year[24]. - The net profit attributable to shareholders of the listed company increased by 12.67% to CNY 39,790,645.55, up from CNY 35,315,527.79 in the previous year[24]. - The gross profit margin decreased to 62.11% from 64.67% year-on-year[24]. - The net cash flow from operating activities decreased by 74.77% to ¥5,195,970.28 compared to ¥20,595,869.57 in the same period last year[26]. - The total operating revenue for the first half of 2023 was CNY 152.71 million, a decrease of 1.80% compared to 155.51 million yuan in the previous year[42]. - Net profit for the period was 39.79 million yuan, an increase of 12.67% from 35.32 million yuan in the previous year, primarily due to increased government subsidies and reduced expenses[42]. - The total comprehensive income for the first half of 2023 was ¥39,779,039.89, compared to ¥35,301,271.67 in the same period last year, marking an increase of approximately 12.03%[126]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 817,351,722.55, down 5.93% from CNY 868,912,246.16 at the end of the previous year[25]. - Total liabilities decreased by 3.39% to CNY 166,911,702.00 from CNY 172,771,172.59 year-on-year[25]. - The net asset attributable to shareholders of the listed company was CNY 650,440,020.55, a decrease of 6.56% from CNY 696,141,073.57[25]. - The company's total assets decreased to CNY 817.31 million from CNY 868.88 million, indicating a reduction in asset base[119]. - Current liabilities totaled CNY 153.95 million, a slight decrease from CNY 157.86 million in the previous year[119]. Cash Flow and Investments - The net cash flow from investment activities was -506.36 million yuan, reflecting a 17.63% increase in outflow compared to -430.49 million yuan in the previous period[65]. - The net cash flow from financing activities was -515.69 million yuan, which is a 21.01% increase in outflow compared to -426.17 million yuan in the previous period[65]. - Cash and cash equivalents decreased by 32.97% to CNY 196.98 million from CNY 293.87 million due to cash dividend distribution and increased financial products[51]. - The company invested a total of 100.5 million yuan in financial products, with an expected balance of 200.5 million yuan remaining[68]. Research and Development - Research and development expenses totaled 12.36 million yuan, accounting for 8.10% of operating revenue, with several new veterinary drug registrations obtained during the period[43]. - The company holds 25 authorized patents, including 16 invention patents and 9 utility model patents, and has developed a new cell culture technology for vaccine production[31]. - The company has successfully developed a new type of classical swine fever vaccine using cell culture, which ranks among the top in market share for its core products[31]. Market and Sales - The poultry division achieved market sales revenue of 22.63 million yuan, a significant increase of 69.16% year-on-year[45]. - Export sales revenue reached 6.95 million yuan, reflecting a growth of 58.64% compared to the previous year[45]. - The company is actively expanding into international markets, currently working on product registrations in countries like Egypt[45]. Corporate Governance and Structure - The company has appointed two new independent directors, Zhang Jianfeng and Ren Tao, to the board[105]. - The total number of employees increased from 335 to 338, with a net addition of 3 employees during the reporting period[109]. - The company has no controlling shareholder or actual controller, and there are no related party relationships among the directors, supervisors, and senior management[102]. Compliance and Risk Management - The company is facing risks related to fluctuations in the livestock industry due to natural disasters and animal epidemics, which could impact vaccine demand[77]. - The company has implemented measures to ensure compliance with environmental regulations, including waste treatment and emissions monitoring[76]. - The company plans to diversify its product line and improve management to mitigate market risks associated with reliance on single products[77]. Shareholder Actions - The company completed a cash dividend distribution of CNY 75,581,106.72, distributing CNY 2.8 per 10 shares to all shareholders[4]. - The company plans to repurchase shares at a maximum price of 11.97 yuan per share, with a total repurchase amount estimated between 21.546 million and 43.092 million[87]. - As of June 30, 2023, the company has repurchased 3,574,800 shares, representing 1.31% of the total share capital, with a total expenditure of approximately 28.63 million yuan[88]. Financial Reporting and Accounting Policies - The company has maintained consistent accounting policies and estimates compared to the previous fiscal year, indicating stability in financial reporting[147]. - The company has not reported any significant changes in the scope of consolidated financial statements or related party transactions[147]. - The company's financial report for the first half of 2023 was approved by the board on August 7, 2023[156].

证券代码：839729 证券简称：永顺生物 公告编号：2023-046 广东永顺生物制药股份有限公司 2022 年年度报告业绩说明会预告公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 说明会类型 本次年度报告业绩说明会将采用网络方式召开，投资者可登陆全景网"投资 者关系互动平台"（https://ir.p5w.net）参与本次年度报告业绩说明会。 三、 参加人员 公司董事、总经理：林德锐先生 公司副总经理、董事会秘书：吴子舟先生 公司财务负责人：李秋红女士 公司保荐代表人：张星明先生 四、 投资者参加方式 本次说明会采用网络方式召开。 投资者可登陆全景网"投资者关系互动平台"（https://ir.p5w.net）参与本次年 度业绩说明会。为充分听取投资者意见，提升交流的针对性，现就公司 2022 年 年度业绩说明会提前向投资者公开征集问题。投资者可于 2023 年 5 月 11 日（星 期四）15:00 前访问 https://ir.p5w.net/zj/或扫描下方二维码，进入问题征集专题 ...

Financial Performance - The company's operating revenue for 2022 was CNY 348,717,555.84, a decrease of 4.07% compared to CNY 363,525,642.57 in 2021[27]. - The net profit attributable to shareholders for 2022 was CNY 86,035,881.94, down 5.81% from CNY 91,342,217.51 in 2021[27]. - The total assets at the end of 2022 amounted to CNY 868,912,246.16, reflecting a growth of 7.38% from CNY 809,181,608.59 at the end of 2021[28]. - The total liabilities increased by 66.45% to CNY 172,771,172.59 in 2022, compared to CNY 103,796,628.70 in 2021[28]. - The company's cash flow from operating activities for 2022 was CNY 69,106,539.37, a decline of 31.38% from CNY 100,703,991.33 in 2021[30]. - The gross profit margin for 2022 was 62.53%, down from 67.43% in 2021[27]. - The weighted average return on equity (ROE) based on net profit attributable to shareholders was 12.38% for 2022, compared to 13.32% in 2021[27]. - The company reported a basic earnings per share of CNY 0.32 for 2022, a decrease of 3.03% from CNY 0.33 in 2021[27]. - The company reported a total non-recurring profit and loss of ¥10,954,801.97 in 2022, an increase of 55.5% compared to ¥7,074,154.63 in 2021[36]. - The company distributed cash dividends totaling 76.36 million yuan based on a plan to distribute 2.8 yuan per 10 shares[55]. Research and Development - The company holds 24 invention patents and 9 utility model patents, with 19 new veterinary drug certificates obtained[12]. - The company has developed two new veterinary vaccines, but market acceptance is currently low, leading to potential revenue risks[13]. - Research and development expenses amounted to 25.38 million yuan, representing 7.28% of operating revenue, with new veterinary drug certificates and patents obtained during the period[51]. - The company is developing a new multi-valent inactivated vaccine for poultry, aiming to enhance immune protection efficiency and product practicality, with the goal of obtaining new veterinary drug certificates and achieving industrialization[100]. - The company is working on a new bivalent inactivated vaccine for swine influenza (H1N1 and H3N2), utilizing MDCK cell culture, which is expected to contribute positively to the development of swine influenza vaccines[100]. - The company is developing a heat-resistant inactivated vaccine for swine diseases, which aims to simplify immunization procedures and reduce stress and infection risks, thereby improving immune efficacy[100]. - The company is advancing the development of a carbon nanotube-based subunit vaccine for the bass virus, addressing urgent needs in the aquaculture industry and aiming for industrialization[100]. - The company is establishing a gene editing technology and recombinant protein expression techniques to create safer and more effective vaccines against major animal diseases[102]. - The company is focusing on the development of multi-valent vaccines to optimize immunization programs and reduce costs for livestock farmers[117]. Market and Industry Risks - The company faces risks related to fluctuations in the downstream livestock and poultry farming industry, which could impact vaccine demand and overall performance[11]. - The company’s main products include high pathogenic avian influenza vaccines, which are subject to national procurement policy changes[11]. - The company faces risks related to the sustainability of cooperative research and technology introduction partnerships[13]. - The company has implemented effective measures to mitigate environmental impact, but risks remain if compliance with environmental standards is not maintained[13]. - The company’s product demand is closely tied to the livestock industry, with potential performance fluctuations due to natural disasters or major animal disease outbreaks[127]. - The company is a designated producer of inactivated avian influenza vaccines, and changes in national procurement policies could adversely affect profitability[128]. Corporate Governance and Compliance - The company has a total share capital of 273,350,000 shares, with 80,244,567 shares (29.36%) being unrestricted and 193,105,433 shares (70.64%) being restricted[174]. - The board of directors consists of 9 members, with no controlling shareholder or actual controller present[199]. - The company has a supervisory board consisting of 3 members[198]. - The company has a total of 3 independent directors, ensuring governance and oversight[198]. - The company has not reported any significant legal disputes or conflicts of interest involving its directors and senior management during the reporting period[162]. - The commitments made by the company and its major shareholders regarding the avoidance of related party transactions are being fulfilled[159]. - The company has confirmed that all commitments made prior to its listing on the New Third Board are being actively fulfilled[154]. Environmental and Social Responsibility - The company reported a wastewater discharge of 61,627.03 tons per year, with treatment systems in place to manage this waste[116]. - The company donated RMB 36,000 worth of epidemic prevention supplies to the authorities in Yanbian, Jilin Province, during the reporting period[115]. - The company has implemented strict biosecurity measures and management systems to mitigate the risk of biological safety incidents during vaccine production[132]. - Environmental protection measures are in place to comply with regulations, but failure to adhere to increasing standards could lead to operational and reputational damage[141]. Shareholder Information - The top three shareholders of Guangdong Yongshun Biological Pharmaceutical Co., Ltd. are Modern Agricultural Group (39.0638%), Guangdong Agricultural Asset Management Co., Ltd. (19.7081%), and the Animal Health Research Institute of the Guangdong Academy of Agricultural Sciences (11.2676%)[181]. - The total number of shares held by the top ten shareholders is 221,714,894, representing 81.1103% of the total shares[178]. - The company has a total of 3,640 common shareholders, indicating a diverse shareholder base[174]. - The company has ongoing commitments from major shareholders to avoid related party transactions and fund occupation, which are currently being fulfilled[153]. Financial Management - The company has secured loans totaling CNY 20,000,000.00 from China Construction Bank at an interest rate of 3% and CNY 9,900,000.00 from Agricultural Bank of China at the same interest rate[192]. - The company has applied for commercial acceptance bill discount financing totaling CNY 62,313,700.00, with an outstanding balance of CNY 27,542,200.00 as of the reporting period end[193]. - The company has complied with regulatory requirements regarding the management and use of raised funds, with no violations reported[188]. - The company has not changed the intended use of the raised funds, and all funds have been used as planned[189].

Financial Performance - Net profit attributable to shareholders for Q1 2023 was CNY 20,894,809.49, representing a growth of 20.58% year-on-year[9] - Operating revenue for the first quarter of 2023 was CNY 81,091,529.35, up 3.07% from the same period last year[9] - Total operating revenue for Q1 2023 reached ¥81,091,529.35, an increase of 3.6% compared to ¥78,677,625.48 in Q1 2022[58] - Total profit reached CNY 23,799,155.91, up from CNY 19,841,045.10, indicating a growth of approximately 19.7%[63] - Operating profit slightly decreased to CNY 18,864,589.14 from CNY 19,833,123.92, a decline of about 4.9%[63] - Basic and diluted earnings per share for Q1 2023 were both ¥0.08, up from ¥0.06 in Q1 2022[60] - The company reported a significant increase in interest income to CNY 1,687,597.44 from CNY 1,188,495.23, representing a growth of approximately 42%[63] - Net profit rose to CNY 20,889,136.99, compared to CNY 17,322,251.00, marking an increase of about 20.5% year-over-year[64] Cash Flow - The company's cash flow from operating activities showed a significant decline, with a net outflow of CNY 14,410,166.78, a decrease of 9283.03% compared to the previous year[13] - Cash flow from investment activities showed a net outflow of CNY 50,994,104.00, a significant increase of 539.85% compared to the previous year[13] - The net cash flow from operating activities was -14,415,846.86, a significant decrease compared to 149,774.03 from the previous period, indicating a decline in operational efficiency[68] - The total cash outflow from operating activities was 76,338,631.09, which is an increase from 61,643,415.40 in the previous period, indicating rising operational costs[68] - The company faced a net cash outflow of 50,994,104.00 from investing activities, highlighting a focus on capital expenditures despite the negative cash flow[68] Assets and Liabilities - Total assets as of March 31, 2023, reached CNY 881,274,401.64, an increase of 1.42% compared to the end of the previous year[9] - The total liabilities to assets ratio remained stable at 19.30% for both the parent and consolidated entities[9] - Total liabilities decreased to ¥170,113,880.59 from ¥172,771,172.59, a reduction of approximately 1.53%[52] - Total equity attributable to shareholders rose to ¥711,160,521.05 from ¥696,141,073.57, an increase of approximately 2.16%[52] - Total non-current assets decreased to ¥244,289,161.03 from ¥251,674,448.53, a decline of about 2.94%[51] - Cash and cash equivalents decreased to ¥257,183,751.02 from ¥293,867,101.54, a decline of about 12.5%[50] Shareholder Information - The total number of shareholders as of the report date was 3,426[17] - The company reported a total share repurchase of 3,055,980 shares, accounting for 1.12% of the total share capital, with a total expenditure of approximately ¥24.60 million, representing 57.09% of the planned repurchase fund limit[31] - The company has a significant shareholder structure, with the largest shareholder holding 39.06% and the second-largest holding 19.71%[22] - The company has successfully implemented its share repurchase plan, achieving 84.89% of the planned repurchase quantity[31] Legal and Compliance - The company is involved in two non-significant lawsuits with a total claim amount of ¥4.98 million, currently in the execution phase[27] - The company has not reported any significant external guarantees or loans during the reporting period[26] - The company has no reported cases of asset seizure, freezing, or other significant legal issues during the reporting period[26] - Major shareholders have signed commitments to avoid competition, which were fulfilled without any violations during the reporting period[33] - Commitments to avoid fund occupation by major shareholders were adhered to without any breaches in the reporting period[34] - The company has maintained compliance with commitments to regulate related party transactions, with no violations reported[35] Research and Development - Research and development expenses for Q1 2023 were ¥6,647,428.05, up from ¥5,504,816.75 in Q1 2022, indicating an increase of 20.7%[59] - R&D expenses increased to CNY 6,647,428.05 from CNY 5,504,816.75, reflecting a growth of approximately 20.7%[63]

Financial Performance - The total operating revenue for 2022 was CNY 348,910,779.14, a decrease of 4.02% compared to the previous year[3] - The net profit attributable to shareholders was CNY 85,800,495.42, down 6.07% year-on-year[3] - Basic earnings per share decreased to CNY 0.31, reflecting a decline of 6.06% from the previous year[3] - The decline in revenue was primarily due to a decrease in technology transfer income by CNY 12,388,000[6] - The company experienced a significant recovery in performance in the second half of the year as pig prices rebounded[5] Assets and Equity - Total assets at the end of the reporting period were CNY 873,148,274.87, an increase of 7.91% compared to the beginning of the year[3] - Shareholders' equity attributable to the parent company was CNY 695,905,687.05, a decrease of 1.34% from the previous year[4] - The company’s net assets per share decreased to CNY 2.55, a decline of 1.16% from the previous year[4] Return on Investment - The weighted average return on net assets (excluding non-recurring items) was 12.35%, down from 13.32% in the previous year[3] Cautionary Note - Investors are advised to be cautious as the financial data presented is preliminary and unaudited, with potential discrepancies in the final annual report[7]